CRVS

Corvus Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · corvuspharma.com

$15.46

After hrs $15.90 -0.75%

Mkt Cap $1.2B

52w Low $3.17 51.7% of range 52w High $26.95

50d MA $15.75 200d MA $10.39

P/E (TTM) -81.4x

EV/EBITDA -14.1x

P/B 19.9x

Debt/Equity 0.0x

ROE -25.0%

P/FCF -18.4x

RSI (14) —

ATR (14) —

Beta 0.97

50d MA $15.75

200d MA $10.39

Avg Volume 1.3M

About

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK,…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 12, 2026	AMC	-0.14	-0.15	-7.1%	16.01	-1.6%	-4.3%	-1.8%	-3.5%	-12.1%	-12.0%	-5.2%	—
Nov 4, 2025	AMC	-0.14	-0.12	+14.3%	7.64	-1.3%	-1.4%	+2.4%	-0.5%	+3.5%	+6.9%	+15.3%	—
Aug 7, 2025	AMC	-0.13	-0.10	+23.1%	4.13	+1.5%	+4.4%	+5.8%	+9.0%	+21.1%	+17.4%	+42.9%	—
May 8, 2025	AMC	-0.13	-0.13	+0.0%	3.35	+26.0%	+32.2%	+21.2%	+16.1%	+8.1%	+6.9%	+20.6%	—
Mar 25, 2025	AMC	-0.12	-0.18	-50.0%	3.93	+1.8%	-14.8%	-14.2%	-14.0%	-19.1%	-19.3%	-6.9%	—
Nov 12, 2024	AMC	-0.11	-0.11	+0.0%	8.69	+14.6%	+2.1%	-2.0%	-5.8%	-4.0%	-3.3%	-7.0%	—
Aug 6, 2024	AMC	-0.12	-0.07	+41.7%	3.00	+6.7%	+9.7%	+19.7%	+32.3%	+22.7%	+25.3%	+33.3%	—
May 6, 2024	AMC	-0.12	-0.12	+0.0%	1.91	-5.2%	-12.0%	+2.6%	+6.3%	+8.9%	+10.5%	+16.2%	—
Mar 19, 2024	AMC	-0.14	-0.14	+0.0%	1.96	-2.0%	-5.6%	-6.1%	-8.7%	-10.2%	-10.2%	-28.1%	—
Nov 7, 2023	AMC	-0.16	-0.12	+25.0%	1.58	+4.4%	+1.3%	-8.9%	-12.0%	-15.8%	-6.3%	+6.3%	—
Aug 8, 2023	AMC	-0.14	-0.14	+0.0%	2.14	+0.5%	+7.9%	+0.0%	+4.7%	+4.2%	+0.9%	-23.4%	—
May 8, 2023	AMC	-0.16	-0.17	-6.2%	1.30	+3.8%	+0.0%	+31.5%	+56.2%	+57.7%	+100.0%	+169.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 13	Oppenheimer	Maintains	Outperform → Outperform	—	$16.01	$15.75	-1.6%	-4.3%	-1.8%	-3.5%	-12.1%	-12.0%
Jan 22	Jefferies	Maintains	Buy → Buy	—	$22.15	$24.30	+9.7%	+15.2%	+13.3%	+3.9%	-0.3%	-7.3%
Jan 21	Barclays	Maintains	Overweight → Overweight	—	$21.41	$21.76	+1.6%	+3.5%	+19.2%	+17.2%	+7.5%	+3.1%
Jan 21	Oppenheimer	Maintains	Outperform → Outperform	—	$21.41	$21.76	+1.6%	+3.5%	+19.2%	+17.2%	+7.5%	+3.1%
Jan 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.05	$13.51	+67.8%	+166.0%	+175.2%	+217.0%	+211.8%	+185.8%
May 20	Mizuho	Maintains	Outperform → Outperform	—	$3.62	$3.60	-0.6%	+1.7%	+0.3%	-4.1%	-3.6%	+1.4%
May 9	Oppenheimer	Maintains	Outperform → Outperform	—	$3.35	$4.22	+26.0%	+32.2%	+21.2%	+16.1%	+8.1%	+6.9%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.93	$4.00	+1.8%	-14.8%	-14.2%	-14.0%	-19.1%	-19.3%
Mar 26	Oppenheimer	Maintains	Outperform → Outperform	—	$3.93	$4.00	+1.8%	-14.8%	-14.2%	-14.0%	-19.1%	-19.3%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.20	$5.18	-0.4%	-1.9%	-5.4%	-9.0%	-3.7%	+0.4%
Nov 13	Oppenheimer	Maintains	Outperform → Outperform	—	$8.69	$9.96	+14.6%	+2.1%	-2.0%	-5.8%	-4.0%	-3.3%
Sep 16	Ladenburg Thalmann	Maintains	Buy → Buy	—	$5.10	$5.25	+2.9%	+13.3%	+7.8%	+7.5%	+10.0%	+15.9%
May 7	Oppenheimer	Maintains	Outperform → Outperform	—	$1.91	$1.81	-5.2%	-12.0%	+2.6%	+6.3%	+8.9%	+10.5%
Mar 27	Mizuho	Maintains	Neutral → Neutral	—	$1.76	$1.77	+0.6%	+1.7%	+1.1%	+5.7%	+5.7%	-0.6%
Mar 20	Oppenheimer	Maintains	Outperform → Outperform	—	$1.96	$1.92	-2.0%	-5.6%	-6.1%	-8.7%	-10.2%	-10.2%
Sep 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$2.09	$2.14	+2.4%	-21.5%	-16.3%	-11.0%	-18.2%	-22.0%
Jun 16	Mizuho	Maintains	Neutral → Neutral	—	$2.49	$2.54	+2.0%	-10.0%	-15.7%	-7.6%	-12.4%	-12.0%
May 30	Ladenburg Thalmann	Maintains	Buy → Buy	—	$2.60	$2.75	+5.8%	+18.8%	+16.9%	+24.6%	+23.1%	+26.2%
May 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.30	$1.35	+3.8%	+0.0%	+31.5%	+56.2%	+57.7%	+100.0%
Mar 30	Mizuho	Maintains	Neutral → Neutral	—	$0.72	$0.76	+5.3%	+10.0%	+26.0%	+37.8%	+49.6%	+38.2%
Oct 7	Ladenburg Thalmann	Maintains	Buy → Buy	—	$0.88	$0.94	+6.3%	+6.3%	+5.0%	+4.1%	+5.1%	+2.9%
Dec 3	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$3.31	$3.41	+3.0%	-6.3%	-6.9%	-1.8%	+0.9%	-5.4%
Dec 1	Jefferies	Maintains	Buy → Buy	—	$3.41	$3.59	+5.3%	-4.1%	-2.9%	-9.1%	-9.7%	-4.7%
Aug 3	Mizuho	Maintains	Neutral → Neutral	—	$2.14	$2.14	+0.0%	-1.9%	-8.4%	-6.5%	-0.5%	-3.7%
Jul 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.33	$2.10	-9.9%	-0.9%	-6.4%	-1.3%	+0.4%	+0.9%
May 27	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$2.66	$2.87	+7.9%	+4.1%	+3.0%	+2.6%	+1.9%	+1.1%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.12	$3.22	+3.2%	-1.6%	-7.1%	-5.8%	-1.3%	+0.6%
Feb 10	Mizuho	Downgrade	Buy → Neutral	—	$4.77	$4.68	-1.9%	-13.0%	-17.4%	-26.6%	-23.7%	-24.5%
Oct 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.86	$4.71	-3.1%	-14.2%	-13.4%	-16.9%	-17.9%	-19.3%
Mar 13	Wedbush	Maintains	Outperform → Outperform	—	$2.47	$2.44	-1.2%	-2.8%	-29.6%	-23.1%	-28.7%	-19.0%
Mar 10	H.C. Wainwright	Maintains	Buy → Buy	—	$2.72	$3.02	+11.0%	+2.9%	-0.4%	-9.2%	-11.8%	-36.0%
Sep 12	Mizuho	Maintains	Buy → Buy	—	$4.15	$4.46	+7.5%	-8.2%	-10.1%	-13.5%	-18.6%	-17.8%
May 29	Roth Capital	Maintains	Buy → Buy	—	$3.90	$4.24	+8.7%	-1.5%	-1.5%	-3.3%	+2.3%	+4.1%
Jun 5	Jefferies	Maintains	Buy → Buy	—	$11.56	$12.09	+4.6%	+5.1%	+12.3%	+12.3%	+11.9%	+11.4%
Aug 24	Credit Suisse	Upgrade	Underperform → Neutral	—	$13.00	$14.03	+7.9%	+12.8%	+11.9%	+11.9%	+17.2%	+22.3%
Aug 3	Wedbush	Maintains	Outperform → Outperform	—	$11.84	$12.31	+4.0%	+1.9%	+3.5%	+2.8%	-1.6%	-4.6%
May 1	Credit Suisse	Downgrade	Outperform → Underperform	—	$9.93	$9.10	-8.4%	-2.9%	+0.2%	-2.5%	-1.9%	+0.6%
Apr 19	BTIG Research	Maintains	Buy → Buy	—	$15.03	$14.87	-1.1%	+1.1%	-0.2%	-0.1%	+0.7%	-1.1%
Apr 18	Guggenheim	Maintains	Buy → Buy	—	$15.61	$15.88	+1.7%	-3.7%	-2.7%	-3.9%	-3.8%	-3.1%
Apr 18	Credit Suisse	Maintains	Outperform → Outperform	—	$15.61	$15.88	+1.7%	-3.7%	-2.7%	-3.9%	-3.8%	-3.1%
Apr 18	Cantor Fitzgerald	Maintains	Buy → Buy	—	$15.61	$15.88	+1.7%	-3.7%	-2.7%	-3.9%	-3.8%	-3.1%

Recent Filings

8-K · 5.02 !!! Very High

Corvus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change

Corvus Pharmaceuticals appointed Andrew C. Chan as a Class II director while Scott Morrison resigned, effective April 23, 2026, signaling potential strategic shifts in board leadership and oversight.

Apr 23

8-K · 1.01 ! Medium

Unknown — 8-K 1.01: Equity Issuance

CRVS's equity issuance agreement with Jefferies suggests potential dilution for existing shareholders, though it may provide needed capital for operations or strategic initiatives.

Mar 13

8-K

Unknown — 8-K Filing

Curvepoint's positive Phase 1 atopic dermatitis data and $189M capital raise significantly extend runway, reducing dilution risk and improving odds of advancing soquelitinib through Phase 2 trials.

Mar 12

Data updated apr 25, 2026 3:25am · Source: massive.com